Laboratorios RichmondC.I.F
Market Cap
AR$12.4b
Last Updated
2021/02/26 22:04 UTC
Data Sources
Company Financials
Executive Summary
Laboratorios Richmond S.A.C.I.F. provides pharmaceutical products and other medicinal specialties. More Details
Rewards
Risk Analysis
Snowflake Analysis
Adequate balance sheet with questionable track record.
Share Price & News
How has Laboratorios RichmondC.I.F's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RICH is not significantly more volatile than the rest of AR stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: RICH's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
20.5%
RICH
-3.8%
AR Pharmaceuticals
-2.6%
AR Market
1 Year Return
75.6%
RICH
-2.0%
AR Pharmaceuticals
25.5%
AR Market
Return vs Industry: RICH exceeded the AR Pharmaceuticals industry which returned -2.3% over the past year.
Return vs Market: RICH exceeded the AR Market which returned 25.8% over the past year.
Shareholder returns
| RICH | Industry | Market | |
|---|---|---|---|
| 7 Day | 20.5% | -3.8% | -2.6% |
| 30 Day | 50.1% | -1.7% | -3.3% |
| 90 Day | 59.9% | 4.4% | -13.7% |
| 1 Year | 75.6%75.6% | 0.7%-2.0% | 26.3%25.5% |
| 3 Year | 533.3%530.6% | 6.9%-1.3% | 33.4%25.0% |
| 5 Year | n/a | 41.2%23.9% | 199.7%162.0% |
Long-Term Price Volatility Vs. Market
How volatile is Laboratorios RichmondC.I.F's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Laboratorios RichmondC.I.F undervalued compared to its fair value and its price relative to the market?
41.63x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RICH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RICH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RICH is poor value based on its PE Ratio (41.6x) compared to the XX Pharmaceuticals industry average (23.6x).
PE vs Market: RICH is poor value based on its PE Ratio (41.6x) compared to the AR market (9.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RICH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RICH is overvalued based on its PB Ratio (5.6x) compared to the XS Pharmaceuticals industry average (3.3x).
Next Steps
Future Growth
How is Laboratorios RichmondC.I.F forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
18.6%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Laboratorios RichmondC.I.F has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Laboratorios RichmondC.I.F's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Laboratorios RichmondC.I.F performed over the past 5 years?
3.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RICH has a high level of non-cash earnings.
Growing Profit Margin: RICH became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: RICH has become profitable over the past 5 years, growing earnings by 3.7% per year.
Accelerating Growth: RICH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: RICH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.2%).
Return on Equity
High ROE: RICH's Return on Equity (13.1%) is considered low.
Next Steps
Financial Health
How is Laboratorios RichmondC.I.F's financial position?
Financial Position Analysis
Short Term Liabilities: RICH's short term assets (ARS4.5B) exceed its short term liabilities (ARS3.5B).
Long Term Liabilities: RICH's short term assets (ARS4.5B) exceed its long term liabilities (ARS752.9M).
Debt to Equity History and Analysis
Debt Level: RICH's debt to equity ratio (45.8%) is considered high.
Reducing Debt: RICH's debt to equity ratio has reduced from 129.8% to 45.8% over the past 5 years.
Debt Coverage: RICH's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: RICH's interest payments on its debt are well covered by EBIT (3.7x coverage).
Balance Sheet
Next Steps
Dividend
What is Laboratorios RichmondC.I.F current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RICH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RICH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RICH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RICH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RICH's dividend in 3 years as they are not forecast to pay a notable one for the AR market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Laboratorios RichmondC.I.F has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Laboratorios Richmond S.A.C.I.F.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Laboratorios Richmond S.A.C.I.F.
- Ticker: RICH
- Exchange: BASE
- Founded: 1935
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AR$12.355b
- Shares outstanding: 80.75m
- Website: https://www.richmondlab.com.ar
Number of Employees
Location
- Laboratorios Richmond S.A.C.I.F.
- Av. Elcano 4938
- Buenos Aires
- Capital Federal
- C1427CIU
- Argentina
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| RICH | BASE (Buenos Aires Stock Exchange) | Yes | Class B Shares | AR | ARS | Dec 2017 |
Biography
Laboratorios Richmond S.A.C.I.F. provides pharmaceutical products and other medicinal specialties. It also offers chemical, synthetic, and plastic products. The company was founded in 1935 and is based in ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/02/26 22:04 |
| End of Day Share Price | 2021/02/26 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.